QuidelOrtho is a diagnostics company formed from the union of Quidel Corporation and Ortho Clinical Diagnostics. The company develops and manufactures diagnostic tests and technologies across the healthcare continuum, from home testing to hospital and clinical laboratory settings. With more than 120 years of collective experience, it operates globally across point-of-care settings, clinical laboratories, and transfusion medicine facilities.
The company's technical capabilities span immunoassay testing, molecular PCR assays, lateral-flow assays, rapid antigen testing, and point-of-care diagnostics. Its product portfolio includes infectious disease tests for HIV, hepatitis C, influenza, strep, and COVID-19, alongside transfusion medicine diagnostics. QuidelOrtho has established several diagnostic firsts: pioneering early lateral-flow pregnancy test strips, developing the first FDA-approved rapid antigen diagnostic test for influenza, and producing among the earliest molecular PCR assays for SARS-CoV-2.
The company combines in-house development and manufacturing capabilities with a mission centred on raising diagnostic performance. Its strategy emphasises delivering vital health information when and where it is needed most, supported by a comprehensive product range that addresses diagnostic requirements across clinical and consumer settings.